- ISIN
- US00972D1054
- CUSIP
- 00972D105
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 20, 2014
Highlights
- Market Cap
- $354.10M
- Enterprise Value
- $216.45M
- EPS (TTM)
- -$0.08
- Total Revenue (TTM)
- $232.40M
- Gross Profit (TTM)
- $188.28M
- EBITDA (TTM)
- $2.84M
- Year Range
- $0.82 - $3.79
- Target Price
- $4.00
- ROA (TTM)
- -5.66%
- ROE (TTM)
- -74.93%
- Avg. Volume (1M)
- 3M
- Avg. Volume Value (1M)
- $4.21M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
AKBA Performance Chart
Akebia Therapeutics, Inc. (AKBA) is down 18.0% since the beginning of the year. At $1 per share, AKBA is trading 65.2% below its 52-week high of $4. Investors who bought $1,000 worth of AKBA shares 5 years ago would now be looking at an investment worth $534.
Loading charts...
Compare this symbol against anything
Returns By Period
Akebia Therapeutics, Inc. (AKBA) has returned -18.01% so far this year and -64.52% over the past 12 months. Over the last ten years, AKBA has returned -17.23% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Akebia Therapeutics, Inc.
- 1D
- -2.22%
- 1M
- 6.45%
- 6M
- -6.38%
- YTD
- -18.01%
- 1Y
- -64.52%
- 3Y*
- -10.48%
- 5Y*
- -11.78%
- 10Y*
- -17.23%
- ALL TIME*
- -20.61%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
AKBA Monthly Returns History
Based on dividend-adjusted daily data since Mar 20, 2014, AKBA's average daily return is +0.06%, while the average monthly return is +1.14%. At this rate, an investment would double in approximately 5.1 years.
Historically, 46% of months were positive and 54% were negative. The best month was Dec 2022 with a return of +113.3%, while the worst month was Sep 2020 at -75.9%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.
On a daily basis, AKBA closed higher 47% of trading days. The best single day was Sep 9, 2015 with a return of +45.5%, while the worst single day was Sep 3, 2020 at -73.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -12.42% | -7.09% | 6.11% | -0.72% | -26.09% | 11.76% | 15.79% | -18.01% | |||||
| 2025 | 17.89% | -17.41% | 3.78% | 25.52% | 25.73% | 20.13% | 1.24% | -14.79% | -13.06% | -19.05% | -28.51% | 1.90% | -15.26% |
| 2024 | 35.48% | -5.95% | 15.82% | -31.15% | -11.11% | -8.93% | 35.29% | 12.32% | -14.84% | 25.76% | 24.10% | -7.77% | 53.23% |
| 2023 | 9.19% | 33.76% | -33.50% | 62.12% | 14.47% | -12.02% | 82.51% | -16.77% | -17.99% | -22.81% | 20.45% | 16.98% | 114.90% |
| 2022 | -11.95% | 8.54% | -66.76% | -42.16% | -10.91% | -4.54% | 10.73% | -6.83% | -13.20% | -19.51% | 6.29% | 113.31% | -74.47% |
| 2021 | 15.71% | 6.79% | -2.17% | -5.76% | 10.03% | 7.98% | -34.83% | 19.03% | -2.04% | -0.35% | -5.57% | -16.61% | -19.29% |
Benchmark Metrics
Akebia Therapeutics, Inc. has an annualized alpha of -2.21%, beta of 1.44, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since March 20, 2014.
- This stock participated in 163.29% of S&P 500 Index downside but only 17.38% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -2.21%
- Beta
- 1.44
- R²
- 0.09
- Upside Capture
- 17.38%
- Downside Capture
- 163.29%
Return for Risk
Risk / Return Rank
AKBA ranks 11 for risk / return — above 11% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Akebia Therapeutics, Inc. (AKBA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AKBA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.27 | ||
| Sortino ratioReturn per unit of downside risk | -3.14 | ||
| Omega ratioGain probability vs. loss probability | 0.84 | 1.25 | -0.42 |
| Calmar ratioReturn relative to maximum drawdown | -0.84 | 2.00 | -2.84 |
| Martin ratioReturn relative to average drawdown | -1.14 | 8.49 | -9.64 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Akebia Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Akebia Therapeutics, Inc. was 99.14%, occurring on Nov 29, 2022. The portfolio has not yet recovered.
The current Akebia Therapeutics, Inc. drawdown is 95.47%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.14%Nov 2022 | 8y 5mo | — | 12y 1moJun 2014 - now | Bear market2022 |
-36.84%Apr 2014 | 21d | 10d | 1mo 1dMar 2014 - Apr 2014 | — |
-21.82%May 2014 | 27d | 21d | 1mo 18dApr 2014 - Jun 2014 | — |
-4.91%Jun 2014 | 7d | 3d | 10dJun 2014 - Jun 2014 | — |
Drawdown Indicators
| AKBA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.14% | -56.78% | -42.36% |
Max Drawdown (1Y)Largest decline over 1 year | -76.94% | -9.10% | -67.84% |
Max Drawdown (3Y)Largest decline over 3 years | -78.23% | -18.90% | -59.33% |
Max Drawdown (5Y)Largest decline over 5 years | -92.51% | -25.43% | -67.08% |
Max Drawdown (10Y)Largest decline over 10 years | -98.73% | -33.92% | -64.81% |
Current DrawdownCurrent decline from peak | -95.47% | -1.58% | -93.89% |
Average DrawdownAverage peak-to-trough decline | -77.51% | -10.70% | -66.81% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 56.14% | 2.14% | +54.00% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Akebia Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Akebia Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AKBA relative to other companies in the Biotechnology industry. Currently, AKBA has a P/S ratio of 1.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AKBA in comparison with other companies in the Biotechnology industry. Currently, AKBA has a P/B value of 12.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with AKBA
Add Akebia Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with AKBA